A partnership between OraSure Technologies (Bethlehem, Pennsylvania) and AbbVie (North Chicago) could put testing individuals at-risk for hepatitis C (HCV) in the forefront of testing for the disease. OraSure held an investor call Wednesday morning to discuss details of the agreement, under which the company and AbbVie will co-promote its OraQuick HCV rapid test in the U.S.

Sitting at the helm of Biodesix (Boulder, Colorado) David Brunel, is coming off a banner year for the company and looking at ways to continue the firm's push for success. The CEO spoke to Medical Device Daily ahead of his attendance at the American Society of Clinical Oncology (ASCO: Alexandria, Virginia) conference held over the weekend and early into this week, and said that the company had gained definite traction and had some more milestones in front of it.